Cargando…

Optimal and safe standard doses of midazolam and propofol to achieve patient and doctor satisfaction with dental treatment: A prospective cohort study

BACKGROUND: The incidences of morbidity and mortality caused by pharmacosedation for dental treatment have not yet reached zero. Adverse events are related to inappropriate respiratory management, mostly originating from an overdose of sedatives. Since sedation is utilized for the satisfaction of bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Rikuo, Nonaka, Mutsumi, Nishimura, Akiko, Gotoh, Kinuko, Oka, Shuichirou, Iijima, Takehiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300152/
https://www.ncbi.nlm.nih.gov/pubmed/28182732
http://dx.doi.org/10.1371/journal.pone.0171627
_version_ 1782506134946447360
author Masuda, Rikuo
Nonaka, Mutsumi
Nishimura, Akiko
Gotoh, Kinuko
Oka, Shuichirou
Iijima, Takehiko
author_facet Masuda, Rikuo
Nonaka, Mutsumi
Nishimura, Akiko
Gotoh, Kinuko
Oka, Shuichirou
Iijima, Takehiko
author_sort Masuda, Rikuo
collection PubMed
description BACKGROUND: The incidences of morbidity and mortality caused by pharmacosedation for dental treatment have not yet reached zero. Adverse events are related to inappropriate respiratory management, mostly originating from an overdose of sedatives. Since sedation is utilized for the satisfaction of both the dentist and the patient, the optimal dose should be minimized to prevent adverse events. We attempted to define the optimal doses of midazolam and propofol required to achieve high levels of patient and dentist satisfaction. METHODS: One thousand dental patients, including those undergoing third molar extractions, were enrolled in this study. A dose of 1 mg of midazolam was administered at 1-minute intervals until adequate sedation was achieved. Propofol was then infused continuously to maintain the sedation level. Both the patients and the dentists were subsequently interviewed and asked to complete a questionnaire. A multivariate logistic regression analysis was used to examine the factors that contributed to patient and dentist satisfaction. RESULTS: The peak midazolam dose resulting in the highest percentage of patient satisfaction was 3 mg. Both a lower dose and a higher dose reduced patient satisfaction. Patient satisfaction increased with an increasing dosage of propofol up until 4 mg/kg/hr, reaching a peak of 78.6%. The peak midazolam dose resulting in the highest percentage of dentist satisfaction (78.8%) was 2 mg. Incremental propofol doses reduced dentist satisfaction, in contrast to their effect on patient satisfaction. The strongest independent predictors of patient satisfaction and dentist satisfaction were no intraoperative memory (OR, 5.073; 95% CI, 3.532–7.287; P<0.001) and unintentional movements by the patient (OR, 0.035; 95% CI, 0.012–0.104; P<0.001), respectively. No serious adverse events were reported. CONCLUSION: We found that 3 mg of midazolam and 3 mg/kg/hr of propofol may be the optimal doses for maximizing both patient and dentist satisfaction. Although this level of sedation is relatively light, memory loss and an absence of unintentional patient movements can be expected without adverse events.
format Online
Article
Text
id pubmed-5300152
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-53001522017-02-28 Optimal and safe standard doses of midazolam and propofol to achieve patient and doctor satisfaction with dental treatment: A prospective cohort study Masuda, Rikuo Nonaka, Mutsumi Nishimura, Akiko Gotoh, Kinuko Oka, Shuichirou Iijima, Takehiko PLoS One Research Article BACKGROUND: The incidences of morbidity and mortality caused by pharmacosedation for dental treatment have not yet reached zero. Adverse events are related to inappropriate respiratory management, mostly originating from an overdose of sedatives. Since sedation is utilized for the satisfaction of both the dentist and the patient, the optimal dose should be minimized to prevent adverse events. We attempted to define the optimal doses of midazolam and propofol required to achieve high levels of patient and dentist satisfaction. METHODS: One thousand dental patients, including those undergoing third molar extractions, were enrolled in this study. A dose of 1 mg of midazolam was administered at 1-minute intervals until adequate sedation was achieved. Propofol was then infused continuously to maintain the sedation level. Both the patients and the dentists were subsequently interviewed and asked to complete a questionnaire. A multivariate logistic regression analysis was used to examine the factors that contributed to patient and dentist satisfaction. RESULTS: The peak midazolam dose resulting in the highest percentage of patient satisfaction was 3 mg. Both a lower dose and a higher dose reduced patient satisfaction. Patient satisfaction increased with an increasing dosage of propofol up until 4 mg/kg/hr, reaching a peak of 78.6%. The peak midazolam dose resulting in the highest percentage of dentist satisfaction (78.8%) was 2 mg. Incremental propofol doses reduced dentist satisfaction, in contrast to their effect on patient satisfaction. The strongest independent predictors of patient satisfaction and dentist satisfaction were no intraoperative memory (OR, 5.073; 95% CI, 3.532–7.287; P<0.001) and unintentional movements by the patient (OR, 0.035; 95% CI, 0.012–0.104; P<0.001), respectively. No serious adverse events were reported. CONCLUSION: We found that 3 mg of midazolam and 3 mg/kg/hr of propofol may be the optimal doses for maximizing both patient and dentist satisfaction. Although this level of sedation is relatively light, memory loss and an absence of unintentional patient movements can be expected without adverse events. Public Library of Science 2017-02-09 /pmc/articles/PMC5300152/ /pubmed/28182732 http://dx.doi.org/10.1371/journal.pone.0171627 Text en © 2017 Masuda et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Masuda, Rikuo
Nonaka, Mutsumi
Nishimura, Akiko
Gotoh, Kinuko
Oka, Shuichirou
Iijima, Takehiko
Optimal and safe standard doses of midazolam and propofol to achieve patient and doctor satisfaction with dental treatment: A prospective cohort study
title Optimal and safe standard doses of midazolam and propofol to achieve patient and doctor satisfaction with dental treatment: A prospective cohort study
title_full Optimal and safe standard doses of midazolam and propofol to achieve patient and doctor satisfaction with dental treatment: A prospective cohort study
title_fullStr Optimal and safe standard doses of midazolam and propofol to achieve patient and doctor satisfaction with dental treatment: A prospective cohort study
title_full_unstemmed Optimal and safe standard doses of midazolam and propofol to achieve patient and doctor satisfaction with dental treatment: A prospective cohort study
title_short Optimal and safe standard doses of midazolam and propofol to achieve patient and doctor satisfaction with dental treatment: A prospective cohort study
title_sort optimal and safe standard doses of midazolam and propofol to achieve patient and doctor satisfaction with dental treatment: a prospective cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300152/
https://www.ncbi.nlm.nih.gov/pubmed/28182732
http://dx.doi.org/10.1371/journal.pone.0171627
work_keys_str_mv AT masudarikuo optimalandsafestandarddosesofmidazolamandpropofoltoachievepatientanddoctorsatisfactionwithdentaltreatmentaprospectivecohortstudy
AT nonakamutsumi optimalandsafestandarddosesofmidazolamandpropofoltoachievepatientanddoctorsatisfactionwithdentaltreatmentaprospectivecohortstudy
AT nishimuraakiko optimalandsafestandarddosesofmidazolamandpropofoltoachievepatientanddoctorsatisfactionwithdentaltreatmentaprospectivecohortstudy
AT gotohkinuko optimalandsafestandarddosesofmidazolamandpropofoltoachievepatientanddoctorsatisfactionwithdentaltreatmentaprospectivecohortstudy
AT okashuichirou optimalandsafestandarddosesofmidazolamandpropofoltoachievepatientanddoctorsatisfactionwithdentaltreatmentaprospectivecohortstudy
AT iijimatakehiko optimalandsafestandarddosesofmidazolamandpropofoltoachievepatientanddoctorsatisfactionwithdentaltreatmentaprospectivecohortstudy